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THE INCREASED RISK OF MORTALITY IN ELDERLY PATIENTS WITH 
EPILEPSY AND DEMENTIAS  
 
 
ROGGER AMERICO ANDRADE 
ABSTRACT 
 Studies have shown that individuals with Alzheimer’s disease or related 
dementias have increased risk of developing seizures. Alzheimer’s disease is the most 
prevalent form of dementia affecting millions of individuals across the nation and as we 
this number continues the rise, we suspect that cases of seizures in elderly patients is on 
the rise as well. Although there are advanced neuroimaging techniques that expand our 
current understanding of neural processes and interplay between neurological diseases, 
we are still limited in our insight into the causes and progression of Alzheimer’s disease 
and related Dementias (ADRD) and epilepsy. We are aware that elderly patients with 
ADRD and epilepsy deteriorate neurologically but it also gives rise to a significant public 
health issue; patients with ADRD and seizures suffer from social, financial and health 
restrictions as well. Overall, there is scarce evidence identifying the impact of having 
comorbid seizures and ADRD. In this study, we performed a retrospective cohort study 
comparing the 5-years mortality risk of patients with both seizures and dementia to 
patients with other neurological conditions. Patient data was retrieved from Research 
Patient Data Registry query and a subsample was selected for medical records abstraction 
using an ICD-9 code for “epilepsy” (345.xx), or “convulsions” (780.3x), or “collapse” 
(780.2x) from 2006-2013 and one claim for ADRD (331.x) within 2006-2013. Our 
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results indicated that the rate of mortality is higher among patients with a history of 
seizures and ADRD when compared to patients seen in neurology for other conditions. 
While previous studies have indicated the increased risk of seizure development in 
elderly patients with ADRD, they did not examine mortality rates. These results amplify 
the need to careful examination of elderly patients who are at risk and can improve the 
quality of care they receive. 
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INTRODUCTION 
The brain is the control center of the body that is responsible for several functions 
critical to survival and daily activities such as breathing and controlling our movements. 
Any disregulation of activity of the brain can lead to catastrophic effects that could be 
detrimental to an individual. The neuron is the basic unit of the brain that is responsible 
for communicating with stimuli from all throughout the body and respond to those 
stimuli. Overstimulation of the brain with excitatory impulses can lead to a seizure, 
which is defined as a transient alteration of behavior due to disordered, rhythmic firing of 
neuron populations that may lead to convulsion, loss of consciousness, etc. (McNamara, 
2011). 
 Studies have shown that individuals with Alzheimer’s disease or related 
dementias (ADRD) are at a greater risk for developing seizures (Vossel et al., 2013). The 
phenomenon of this occurrence is poorly understood but is a major public health concern 
for the elderly population. A lingering question is whether the neurological effects that 
epilepsy has plays a role in the development of ADRD, does ADRD symptoms lead to 
seizure activity or are the anticonvulsive therapeutics on the market today a factor 
playing a role in ADRD development. 
 
Etiology of Epilepsy and Seizures 
Epilepsies are common neurological disorders that affect over 2.5 million 
individuals of United States (US) population (McNamara, 2011). With the various 
classifications of epilepsy available (Figure 1) (Hirsch et al., 2016)., this leads to an 
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expansive list of possible of epilepsy diagnoses This makes it is difficult to discover the 
underlying cause of each case, many of which are incurable (Moura et al., 2016). The 
goal of treatment is to minimize the occurrence of spontaneous seizure with continuous 
use of antiepileptic drug (AED) treatment (Galimberti et al., 2006).  
Figure 1. The International League Against Epilepsy (ILAE) 2016 Operational 
Classification of Seizure Types: Expanded. (Figure amended from Hirsch	et	al.,	2016). 
 
The two critical neurotransmitters involved in seizure activity are the excitatory 
neurotransmitter (NT) glutamate and inhibitory NT γ-Aminobutyric acid (GABA). The 
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imbalance of these NTs leads to disregulation of neuronal impulses resulting in seizure 
activity (McNamara, 2011). Important types of glutamate receptors associated with 
seizures are the ionotropic N-4 methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) receptors and kainic acid (KA) receptors. 
NMDA receptors are calcium (Ca2+)-permeable that elicits a slow, long lasting excitation 
in response to synchronous glutamate binding and membrane depolarization, which 
overcomes their blockage by Mg2+. The Ca2+ influx triggers the activation of a number of 
kinases that increase both AMPA receptor ion conductance and AMPA receptor 
trafficking to the post-synaptic membrane (Breedlove et al., 2007). Activation of NMDA 
receptors is required for inducing a type of long-term potentiation (LTP), which takes 
place in the hippocampus that is essential in learning and memory. AMPA receptors and 
KA receptors regulate rapid depolarization at glutamatergic synapses in the central 
nervous system (Molinoff, 2011).  Excessive glutamate levels can result in neuronal cell 
death by downstream activation of mechanisms that is though to be triggered by 
excessive activation of NMDA or AMPA/kinase receptors, allowing significant influx of 
Ca2+ into neurons (Figure 2) (Molinoff, 2011). This over excitation of neuronal impulses 
can lead to seizures and other neurological conditions. Comparatively, GABA receptors 
are crucial for hyperpolarizing and are permeable to Cl-. Altering these receptors can 
affect their inhibitory effects and result in the inability to prevent extensive 
hyperexcitability. 
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Figure 2. Mechanisms contributing to neuronal injury during ischemia-reperfusion. 
Various pathways contribute to neuronal excitotoxicity and injury in ischemia, with 
excess cytosolic Ca2+ playing a precipitating role. DAG, diacylglycerol; GluR, 
AMPA/kainate type of glutamate receptors; IP3, inositol trisphosphate; mGluR, 
metabotropic glutamate receptor; NMDA-R, N—methyl-D-aspartate receptor; O2−, 
superoxide radical; PIP2, phophatidyinositol 4,5-bisphosphate; PKC, protein kinase C; 
PL, phospholipids, PL phospholipase, VSCC, voltage-sensitive Ca2+ channel. COX, 
cyclooxygenase; LOX, lipoxygenase; NCX, NA+/Ca2+ exchanger; mtPTP, mitochondrial 
permeability transition pore. (Figure amended from Molinoff, 2011). 
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Epilepsy and Antiepileptic Drugs 
Antiepileptic drugs (AEDs) are used to reduce seizure frequency (SF), either by 
increasing inhibition (GABA-agonist) or decreasing activation (Glutamate-antagonist) of 
a particular voltage-gated calcium channel known as T-current (McNamara, 2011). With 
many AEDs available on the market [Table 1](Sirven et al.,  2012), they are categorized 
by their clinical mechanisms of action. These mechanisms include the modulation of 
voltage-dependent Na+ channels, enhancing synaptic inhibition my modulating levels of 
GABA, either presynaptically or postsynaptically and inhibition of synaptic excitation, 
focused primarily on the inhibition of voltage-gated Ca2+ channels responsible for T-type 
Ca2+ currents (Levy, 2002). 
 
Table 1. Antiepileptic Drugs and Devices Currently Approved by the Food and 
Drug Administration. (Table amended from Sirven et al.,  2012). 
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In addition, epilepsy is often comorbid with other neurological and psychological 
conditions, making a specific treatment a challenge (Deonna & Roulet, 2006; LaFrance et 
al., 2008). 
 
Misdiagnosing Epilepsy 
 Diagnosing individuals with epilepsy can be difficult. The general criteria for 
diagnosis of epilepsy is the occurrence of two or more unprovoked seizures in over a 24 
hour period (“Guidelines for Epidemiologic Studies on Epilepsy,” 1993). A complete 
diagnosis of epilepsy requires differentiation of seizures from other possible alterations of 
consciousness and/or behavior, unprovoked seizures versus provoked seizures, seizure 
classification and discovering the underlying cause (Smith, 1999). In order to obtain a 
diagnosis, clinicians rely on a variety of methods. These methods include: 
(1) Imaging techniques such as Magnetic Resonance Imaging (MRI) and 
Computerized Tomography (CT) scans. 
 (2) Electroencephalogram (EEG) scans that detect electrical activity in the brain. 
 (3) Individual and eye-witnessed accounts of episodes. 
 (4) Discussion of symptoms and other conditions. 
Even with careful examination, it is extremely difficult to reach an unequivocal diagnosis 
due to atypical seizure presentations, insufficient patient history or relevant symptoms 
that are due to another manifestation. 
 Cases that appear similar to seizure activity include syncopal episodes, 
psychogenic attacks, and migraines. As a result, individuals are started on AEDs as a 
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result of an epilepsy diagnosis or for seizure prophylaxis. With an estimated 20% of 
patients attending specialty epilepsy clinics who do not actually have epilepsy (Scheepers 
et al.,  1998), it is an epidemiological problem that can result in missing a correct 
diagnosis or patients suffering from long-term effects of AED treatment.  
 
Etiology of Alzheimer’s Disease 
 Dementias are defined as chronic or persistent disorders of central nervous system 
(CNS) processes caused by brain disease or injuries that are characterized by memory 
decline, changes in personality and affected reasoning. A specific type of dementia that 
leads to the memory and functional neuronal degeneration is Alzheimer’s disease (AD).  
This progressive neurodegenerative disorder is the most prevalent form of dementia in 
individuals who are older than 65 and affects over 5.3 million American worldwide; a 
number that is expected to multiply in the near future (Kirson et al., 2016).  
 AD is presented in both genetic and sporadic forms. The occurrence of familial 
AD is extremely rare and accounts for less than 1% of all AD cases (Talwar et al., 2016). 
Familial forms of AD are characterized by early-onset AD (before the age of 50). These 
cases are shown to be the result of mutations in proteins amyloid precursor protein 
(APP), PSEN1 and PSEN2 have been identified (Tanzi & Bertram, 2005). These 
mutations alter the proteolysis of different APP isomers resulting in the increased 
amyloidic generation of amyloid-beta (Aβ) protein fragments generated through the 
alternative cleavage of APP by β- and γ-secretases, instead of normal α-secretase 
cleavage (Figure 3) (Talwar et al., 2016).  Αβ peptides (Aβ42) generated through the 
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amyloidogenic pathway are susceptible to aggregation and can lead to the toxic Aβ 
oligomers and plaque formation (Tosto & Reitz, 2016).  
 
Figure 3. Role of APP in AD. 
a. APP isoforms and domain structure: A 240-kb gene on chromosome 21q21.3, with 19 
exons encodes APP. APP is a 110–135-kDa protein consisting of 365 to 770 amino acid 
residues divided into nine structural domains, that have at least eight isoforms formed due 
to alternate splicing. 
Three major isoforms (APP770, APP751, and APP695) are formed by alternative 
splicing of exons encoding the Kunitz-type serine protease inhibitors (KPI) domain (exon 
7) and the MRC antigen OX-2 homologous domain (exon 8). The APP695 is the most 
prevalent isoform found in neuronal cells. 
b. The Proteolytic processing of APP: The proteolytic cleavage of APP by β- and γ-
secretase creates a Aβ fragment that is composed of a 39 to 43 amino acid residue 
sequence that is encoded by exons 16 and 17. (Figure amended from Talwar et al., 2016). 
 
	9 
In sporadic cases, the progression of AD can be due to natural aging and loss of 
neuronal function but a specific allele identified has shown to determine the susceptibility 
of developing AD; this allele is APOE-ε4 (Bertram et al.,  2007). Individuals with this 
allele have more than a 3-fold higher risk of developing AD and make up over 50% of 
population of all AD cases (McNamara, 2011). Apolipoprotein E (APOE) is a 299 amino 
acid glycoprotein that exists in 3 different isoforms: APOE-ε2, APOE-ε3, and APOE-ε4. 
Even healthy carriers of the APOE- ε4 allele show progressive memory decline, lower 
levels of cerebral glucose metabolism, as well as hippocampal atrophy (Reiman et al., 
1998). 
Animal studies show that the APOE-ε4 allele leads to impairment of memory and 
spatial learning without the accumulation of Aβ42, as well as impaired synaptogenesis in 
APOE transgenic/knock-in mice and neuronal branching inhibition and extension in vitro 
(Huang, 2010). Different APOE isoforms are shown to bind distinctly to the Aβ42 peptide 
and tau protein (Strittmatter et al., 1993, 1994). For example, the APOE-ε4 isoform binds 
to the Aβ42 peptide faster than APOE-ε3 leading to the formation of fibrils that aggregate 
resulting in plaque formation (Sanan et al., 1994).  
 
Pathophysiology of Alzheimer’s Disease 
This devastating disease is characterized by the accumulation of APP-derived Aβ 
peptides and neurofibrillary tangles comprised of hyperphosphorylated protein tau (Ma et 
al.,  2012). This accumulation leads to cell death due to stress caused by the development 
of reactive oxidative species (ROS) (Petersen et al., 2005), damage which is most 
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vulnerable in the medial temporal lobe (McNamara, 2011). The damage done to the brain 
macroscopically can be seen remarkably well using imaging techniques such as an MRI. 
The atrophy that occurs in AD is most conspicuous in the three of four lobes of the brain 
(frontal, parietal and temporal), with much of the protein aggregates found within the 
neuronal cytoplasm in the neocortex, hippocampus, basal forebrain, and certain brainstem 
areas (Figure 4) (Richardson, 2002). This neurodegeneration results in the destruction of 
acetylcholine (ACh) receptors and the dysfunction of the enzyme choline 
acetyltransferase resulting in an extraordinary reduction of the NT ACh. This hallmark is 
what contributes to the devastating loss of memory in patients with AD (Richardson, 
2002). In both familial and sporadic cases, there is an oligomerization and deposition of 
Aβ that can cause an inflammatory response that initiates a downstream cascade that 
results in neurodegeneration (Figure 5) (Talwar et al., 2016). 
 
 
 
 
 
Figure 4. Microscopic Imaging of Neurofibrillary Tangles and 
Hyperphosphorylated Tau 
(A) A section of the hippocampus of an elderly patient with AD is stained with 
hyperphosphorylated tau protein antibody. The result demonstrates densely staining 
neurofibrillary tangles within the cell bodies of neurons.  
(B) An immunohistochemistry was performed on a case like that of (A) and demonstrates 
the presence of plaque, composed an accumulation of swollen neuronal cell processes 
loaded down with hyperphosphorylated tau. Diaminobenzidine-labeled section ×400. 
(Figure amended from Richardson, 2002). 
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Figure 5. Pathophysiological changes leading to onset of AD. The downstream 
cascade of the development of AD. (Figure amended from Talwar et al., 2016). 
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Treatment of Alzheimer’s Disease 
Alzheimer’s cannot be definitively diagnosed until a post-mortem autopsy is 
performed and confirms the presence of dense Aβ plaques, elements of 
neurodegeneration, neurofibrillary tangles with hyperphosphorylated tau, and loss of 
synapses within the brain (Wood et al.,  1999). Since AD cannot be 100% confirmed until 
the death of a patient, certain criteria have been established to determine the likelihood of 
an AD diagnosis [Table 2] (Wood et al., 1999). 
 
Table 2. Criteria for Diagnosis of Alzheimer’s Disease. (Table amended from Wood et 
al., 1999). 
With no cure, the goals of treatment in AD patients have been to slow down the 
progression of memory loss and cognition as well as to maintain an individual’s ability to 
perform daily functions independently. With the loss of ACh being a major contributor to 
the pathology of AD, treatment is targeted in preventing more loss and increasing the 
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amount of ACh in the brain. Currently, the use of anticholinesterases (AChIs) has shown 
to be affective in increasing the levels of ACh in the brain. AChIs increase cholinergic 
synaptic transmission by inhibiting acetylcholinesterase in the synaptic cleft, resulting in 
decreased ACh degradation (Wood et al., 1999). Another form of treatment aims to 
reduce the accumulation of ROS that to cell death and contributes to the pathology of 
AD. Many studies have shown that the use of antioxidants are affective in reducing free 
radical formation and oxidative stress as well as increasing the survival of neurons that 
have been exposed to β-amyloid. Results from those studies vary from how long 
progression of disease delayed to improvement in Alzheimer’s Disease Assessment 
Scale, Cognitive Subscale scores [Table 3] (Wood et al., 1999). 
Table 3. Drugs Used to Slow or Delay the Progression of AD. 
*Percentages indicate the changes in treated group corrected for placebo group changes.  
†Progression was measured by the time until death, nursing home placement, inability to 
perform daily activities, or severe dementia. In the group treated with α-tocopherol and 
selegiline, the incidence of falls and syncope was 22 and 16 percent respectively.  
‡This test correlates with the cognitive subscale of the AD Assessment Scale and the 
change shown represents a 3 percent benefit as compared to placebo on this scale. (Table 
amended from Wood et al., 1999). 
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Epilepsy and Dementia in Elderly 
Seizures, more common among older adults (65+ years), will befall 
approximately 10% of adults at some point in their life (Faught et al., 2012; Beghi et al., 
2005; Reid et al., 2012; St. Germaine-Smith et al., 2012; Griffith et al., 2007; Perucca et 
al., 2006; Galimberti et al., 2006; McWilliams et al., 2013; Brodie & Stephen, 2007). 
Studies have shown that risk factors for seizures include a history of Alzheimer’s disease 
or related dementias with an incidence rate as high as 5.6-7.5/1000 (Faught et al., 2012; 
Hesdorffer et al., 2011; Leppik, 2007; Kotsopoulos et al., 2002; Pugh et al., 2007; 
Ramsay et al.,  2007; Ruggles et al., 2002; Brodie et al.,  2009; Imfeld et al., 2013).  
The toxic aggregation of Aβ peptides underlying AD triggers loss of synapses, 
remodeling of neuronal circuits, and dysfunction in synchronizing signals within the 
hippocampus and neocortex, which may lead to hyperexcitability and the development of 
seizures, in addition to the neurological degeneration associated with AD and related 
dementias. In fact, the hippocampus, a well-recognized area of ADRD-associated 
atrophy, is the most common (>60%) site of seizure localization in elderly patients who 
experience focal dyscognitive seizures (impaired consciousness)(Nussbaum et al.,  2013; 
Tanaka et al., 2013). With these recent findings, it is critical to analyze the risk factors 
associated with the seizure development in elderly patients with ADRD. 
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The Neurocognitive Impact of Epilepsy and ADRD 
Recurrent seizures (epilepsy) also increase the likelihood of developing ADRD. A 
number of potential conditional factors that can impact cognitive function have been 
described in patients with recurrent seizures, including vascular disease, altered wall 
thickness of the carotid artery, atherosclerotic inflammation, and recent studies 
suggesting that seizures facilitate production of Aβ peptides.(Hermann et al., 2008) In 
addition, many drugs for seizure prophylaxis and treatment can affect metabolic balance, 
which can contribute to conditions that increase the risk of vascular dementia (e.g., 
hyperinsulinemia, hyperhomocysteinemia)(Hermann et al., 2008). Long term AED 
treatment has been shown to cause damage in the developing brain causing impairments 
in learning, memory and attention (Shi et al., 2010), thus AED treatment in elderly must 
be monitored carefully. 
Advanced neuroimaging techniques continue to build upon existing knowledge 
about our neural mechanisms and the complex interplay between neurological diseases. 
Translational scientists have yet to bring new insights into the cause and progression of 
ADRD and epilepsy, as well as opportunities for more effective treatments. Meanwhile, 
clinical and population-based scientists highlight that older adults with both seizures and 
ADRD suffer from serious social, financial and health restrictions.(Brodie & Stephen, 
2007; Faught et al., 2012; Hesdorffer et al., 2011; Kotsopoulos et al., 2002; Leppik, 2007; 
Pugh et al., 2007; Ruggles et al., 2002) Nonetheless, there is still a dearth of evidence 
surrounding the impact of having co-morbid seizures and ADRD. 
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Medicare Beneficiaries 
Medicare is the major public insurance program for older Americans, serving over 
55 million older adults. Increasingly, beneficiaries are choosing to enroll in Medicare 
Advantage (MA) rather than in traditional, fee-for-service Medicare (TM). This choice of 
Medicare program could be important for clinical care because the private MA plans 
actively manage the provider networks, employ utilization management strategies to 
influence practice patterns, but also offer more generous insurance coverage and 
potentially programs to help coordinate complex care. MA plans also use a number of 
financial incentives to monitor and improve quality of care including the introduction of 
MA quality bonuses, which has likely accelerated these quality efforts. Arguably, most of 
the bonuses and quality programs have focused on relatively common, primary care 
oriented conditions such as diabetes. There has been considerably less attention to 
complex clinical conditions such as ADRD patients with seizures or to the role of 
specialists in this care. Medicare, however, has been introducing a number of reforms and 
demonstrations to improve TM care too (e.g., accountable care organizations 
(ACOs))(The Henry J. Kaiser Family Foundation, 2014). 
 
The Present Study 
In this study, we defined the mortality rate in a population of older adults with 
history of both seizures and ADRD, who were publicly insured in the US and seen in a 
major academic neurology department. We then compared the 5-year mortality risk of 
patients with both seizures and dementia to patients with other neurological conditions as 
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well as demographics to determine if certain characteristics displayed statistically 
significant increases in the risk of developing comorbid seizures and ADRD. In addition, 
we analyzed the types of epilepsy diagnoses, AEDs given and seizure frequency through 
chart abstraction to obtain more information about patient’s seizure history. 
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SPECIFIC AIMS 
In order to discover the mortality rate of patients with comorbid epilepsy and ADRD we 
aim to: 
 (1) Examine the accuracy of an algorithm that screens patients with high 
probabilities of having both a diagnosis of dementia and a history of seizures. 
 (2) To compare mortality rates in elderly patients with high probability of 
developing comorbid seizures and ADRD versus those with low probability. 
 We expect that this study will show: 
 (1) Patients with ADRD and seizures to have an increased risk of mortality. 
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METHODS  
In this study, a retrospective review of linked data was performed and validated 
by medical records review of a subsample. 
 
Participants and Data Collection 
 
We targeted Medicare beneficiaries as a representative and vulnerable group of 
older patients, for which our findings could significantly impact decisions made by policy 
makers.   
Data samples were retrieved from: 
(A) Administrative and clinical data using a Research Patient Data Registry 
(RPDR) query tool, a centralized registry of clinical data that amass data from sources 
found in Partners Healthcare System (PHS) including medical records, reporting, claims 
and administration information. 
(B) Information from the Social Security Death Master File available in the 
Research Patient Data Registry. 
(C) Epic-based Electronic Health Records (EHR) of a subsample. 
For the purpose of this study, the query was limited to the department of neurology of the 
Massachusetts General Hospital (MGH).  
The Death Master File is a limited access dataset assembled by the Social 
Security Administration (SSA), which has information pertaining to the date of death 
created from SSA payment records. The date of death information is updated on every 
patient registered with the PHS independent of individual healthcare utilization.  
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The collection of patients was obtained using the RPDR query tool in the PHS 
and yielded a sample of 8275 eligible Medicare beneficiaries, who had at least one 
outpatient appointment at the Neurology department within 2006-2013, and who were 
older than 62 by 2013. By default, PHS employees were not included in the RPDR in 
order to comply with privacy guidelines. Queried variables included age, gender, 
ethnicity, marital status, religion, patient’s medical conditions and medication list. The 
main outcome was mortality (date of death), which was gathered from the Death Master 
File with respect to the years of 2006-6/2016.    
 
Chart Abstraction and Validation  
A subsample of 394 records was selected for structured medical records 
abstraction (validation sample). This screening was performed using ICD-9 codes 
available in the RPDR query tool. Included patients had either one claim with an ICD-9 
code for “epilepsy” (345.xx), or “convulsions” (780.3x), or “collapse” (780.2x) from 
2006-2013 and one claim for ADRD (331.x) within 2006-2013.  
For the validation work, standardized medical records abstraction was performed. 
Information recorded included demographic data, including vital status, cause of death 
(when available), age of death, gender, primary language, race, and the level of care 
received within the time frame (i.e., listed each of the Neurology sub-divisions within the 
Neurology department). When applicable and available, abstracted clinical information 
also included vital status, cause of death, age of death, number and type of medications, 
Alzheimer’s disease or related dementia diagnosis status and classification, seizure 
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history. For patients with history of seizures, age at first seizure, seizure type, epilepsy 
syndrome, seizure frequency, epilepsy syndrome and etiology, results of brain imaging 
(brain MRI or head CT), and results of EEG were recorded. Seizure frequency was 
defined as the average number of seizure episodes during the past 6 months of the most 
recent visit. 
In order to compare reliability, a comparison of three independent reviews of 40 
randomly selected medical records was performed. Inter-rater reliability was high (kappa 
> 0.8) on the key measures (i.e.: Alzheimer’s disease or related dementia diagnosis and 
seizure history).  
For ADRD, charts were reviewed and ascertained the diagnosis of ADRD based 
on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). In 
brief, DSM-5 recognizes two cognitive syndromes: major neurocognitive impairment and 
mild neurocognitive impairment (Dubois et al., 2010). Patients were dichotomized with 
vs without diagnosis of ADRD.  
For consistency, in case of ascertainment of seizure history, evidence that justifies 
a substantial risk for having seizures based on the updated 2014 criteria for epilepsy 
diagnosis adopted by the ILAE was documented. Substantial risk for having seizures is 
defined as a risk that is greater than the average comparable population (i.e., >60% risk to 
occur over the next 10 years). We considered patients with high risk for having seizures 
those who had evidence of:  
(A) Two or more unprovoked seizures occurring more than 24 hours apart. 
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(B) One seizure and probability of recurrence greater than 60% based on 
neurologist’s assessment. 
(C) Clinical diagnosis of an epilepsy syndrome (e.g., Idiopathic generalized 
epilepsy). 
(D) One single seizure and structural abnormalities evidenced in brain imaging,  
(E) Probability of seizure occurrence greater than 60% (i.e., long-term anti-
seizure prophylaxis) based on neurologist’s assessment.  
Patients considered having a low or average risk for seizures those who had no evidence 
of previous seizures. Some of them had non-epileptic events, syncope, collapse, or there 
was insufficient information available in the chart to allow for ascertainment of 
underlying risk of seizures.  
 
Statistical Analysis 
The final cohort was categorized according to the history of seizures associated 
with a diagnosis of Alzheimer’s disease or related dementias (yes vs. no). As described in 
the screening process, patients of the “yes” (high risk) group had at least one outpatient 
claim (ICD-9 code) suggestive of epilepsy or seizures and one code suggestive of 
Alzheimer’s disease or related dementias within 2006-2013.  The “no” (low risk) group 
included all other patients that did not meet the criteria above but were still seen at the 
same neurology department within the same time frame.  
T-tests were performed to compare the mean age of patients between the groups. 
In addition, the chi-square test of independence was utilized to determine whether the 
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categorical variables that were assessed displayed any association with increased rates of 
mortality: gender, ethnicity, preferred language, marital status for both baseline and 
validation sample cohort. For categorical variables, a non-normal distribution was 
assumed and the percentages, confidence intervals, medians, and interquartile ranges 
were described. To assess the mortality risk associated with having possible history of 
seizures and dementia, the chi-square test and multivariable logistic regression (entire 
sample, claims-based algorithm) was used.  
Using the validation sample, the results of the categorization based on the claims-
based algorithm were compared with the gold standard categorization obtained by chart 
abstraction. The sensitivity and specificity of the claims-based algorithm for 
identification of history of seizures associated with a diagnosis of Alzheimer’s disease or 
related dementias was then calculated. Similar to the main analysis, logistic regression 
was used examine the mortality risk associated with having a confirmed previous history 
of seizures and dementia (validation sample, gold standard categorization).  
For all analyses, the statistical significance level was defined as p < 0.05. SAS® 
Studio software package (SAS Institute Inc. Cary, NC) was used to merge datasets and to 
perform statistical analysis. This study was conducted and approved by the Review Board 
(IRB). 
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RESULTS 
Cohort Distribution 
 
 We defined a significant p-value to be <0.05. In the baseline cohort [Table 4] 
there was evidence of significant differences in categorical variables associated with low 
and high risk groups. The baseline cohort consisted of a sample of 8275 eligible 
Medicare beneficiaries, who had at least one outpatient appointment at the Neurology 
department within 2006-2013. The high risk group show to be on average older than the 
subjects in the low risk group (74.5 vs 73.1; p = 0.01). In addition, there were a smaller 
percentage of veterans in the high risk group in comparison to the low risk group.  
Table 4. Cohort Baseline Characteristics. 
 
*A list of patients was obtained using the RPDR query tool in the PHS and yielded a 
sample of 8275 eligible Medicare beneficiaries, who had at least one outpatient 
appointment at the Neurology department within 2006-2013, and who were older than 62 
by 2013. Queried variables included age, gender, ethnicity, marital status, religion, and 
veteran status.  
The total N varies in each variable due to missing/insufficient data in charts. 
 Whole sample High risk group Low risk group p-value 
Demographic 
Characteristics (Total N) 
N = 8275* N = 250 N = 8025  
Mean Age, +/- SD 73.2 (8.7) 74.5 (8.6) 73.1 (8.7) 0.01 
Male Sex, (%) 3990 (48.2) 117 (46.8) 3873 (48.3) 0.65 
Marital Status  N= 7911 N= 240 N = 7671 0.41 
     Married, (%) 4142 (52.4) 114 (47.5) 4028 (52.5)  
     Other, (%)  3769 (47.6) 126 (52.5) 3643 (47.5)  
Race N= 7857 N= 240 N= 7617 0.28 
     White, (%) 7167 (91.2) 218 (90.8) 6949 (91.2)  
     Other, (%) 72 (0.9) 0 (0.0) 72 (1.0)  
Religion N= 6600 N= 212 N= 6388 0.95 
     Christian, (%) 5949 (90.1) 188 (88.7) 5761 (90.2)  
     Other, (%) 651 (9.9) 24 (11.3) 627 (9.8)  
Veteran Status N = 7304 N = 234 N = 7070 0.03 
     Veteran, (%) 1629 (22.3) 49 (20.9) 1580 (22.3)  
     Not a Veteran, (%) 5675 (77.7) 185 (79.1) 5490 (77.7)  
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Of the validation sample [Table 5], there was not a presence of significant differences in 
the characteristics of those in the low risk vs high risk group. 
 
Table 5. Validation Cohort Characteristics.  
*A subsample of 394 records was selected for structured medical records abstraction 
(validation sample). This screening was performed using ICD-9 codes available in the 
RPDR query tool. Included patients had either one claim with an ICD-9 code for 
“epilepsy” (345.xx), or “convulsions” (780.3x), or “collapse” (780.2x) from 2006-2013 
and one claim for ADRD (331.x) within 2006-2013.  
The total N varies in each variable due to missing/insufficient data in charts. 
 
 
 
 
 
 Whole 
validation 
sample 
High risk 
group 
Low risk 
group 
p-value 
Demographic 
characteristics 
N = 394* N = 250 N = 144  
Mean Age in 2006 (+/- SD) 73.7 (8.6) 73.6 (8.6) 73.8 (8.6) 0.79 
Male Sex, % 213 (54.1) 113 (53.2) 80 (55.6) 0.65 
Marital Status  N = 382 N = 240 N = 142 0.24 
     Married, (%) 183 (47.9) 114 (47.5) 69 (48.6)  
     Other, (%)  199 (52.1) 126 (52.5) 73 (51.4)  
Race N = 380 N = 240 N = 140  
     White, (%) 349 (91.8) 218 (90.8) 131 (93.6)  
     Other, (%) 31 (8.2) 22 (9.2) 9 (6.4)  
Religion N = 332 N = 212 N = 120 0.13 
     Christian, (%) 285 (85.8) 188 (88.7) 97 (80.8)  
     Other, (%) 47 (14.2) 24 (11.3) 23 (19.2)  
Veteran Status N = 371 N = 143 N = 228 0.12 
     Veteran, (%) 79 (20.2) 27 (17.4) 52 (21.9)  
     Not a Veteran, (%) 292 (74.5) 116 (74.8) 176 (74.3)  
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Comparison of Sample with Confirmed Epilepsy vs. Without Epilepsy 
 Of the total sample used for validation of the sampling method (N = 394), 6 
patients were excluded from the determination of an epilepsy diagnosis due to 
insufficient records (N = 388). Insufficient records consisted of absence of details of 
notes that did not allow us to accurately infer a patient’s status. Of that total, 177 patients 
were confirmed to have epilepsy and 211 were not diagnosed with epilepsy. A variety of 
information was compared of between the two groups [Table 6]. 
Table 6. Comparison of Validation Cohort with Confirmed Epilepsy and No 
Epilepsy. 
 Whole 
validation 
sample 
Confirmed 
Epilepsy 
Epilepsy 
Diagnosis Not 
Confirmed 
p Value 
Demographic characteristics N = 388* N = 177 N = 211 0.016 
Age in 2006 N = 382 N = 148 N = 232 <0.001 
     Mean, (SD) 75.1 (8.2) 71.7 (8.4) 75.4 (8.4)  
Male sex, (%) 234 (60.3) 108 (61.0) 126 (59.7) 0.79 
Marital Status  N = 376 N = 172 N = 204 0.61 
     Married, (%) 179 (47.6) 88 (51.1) 91 (44.6)  
     Other, (%)  197 (52.4) 84 (48.9) 113 (55.4)  
Race N = 374 N = 171 N = 203 0.015 
     White, (%) 345 (92.3) 151 (88.3) 194 (95.6)  
     Other, (%) 29 (7.7) 20 (11.7) 9 (4.4)  
Religion N = 339 N = 159 N = 180 0.28 
     Christian, (%) 277 (81.7) 132 (83.0) 145 (80.6)  
     Other, (%) 62 (18.3) 27 (17.0) 35 (19.4)  
AED N = 207 N = 161 N = 46 <0.0001 
     Gabapentin, (%) 17 (8.2) 2 (1.2) 15 (32.6)  
     Levetiracetam, (%) 50 (24.2) 44 (27.3) 6 (13.0)  
     Phenytoin, (%) 18 (8.7) 16 (9.9) 2 (4.4)  
     More than one, (%) 72 (34.8) 67 (41.6) 5 (10.9)  
     Other, (%)  50 (24.2) 32 (19.9) 18 (39.1)  
Other Medications N = 386 N = 176 N = 210 <0.0001 
     Mean, (SD) 10.0 (6.2) 10.2 (7.1) 10.0 (5.3)  
Age at first seizure N = 131 N = 127 N = 4 <0.11 
     Mean, (SD) 70.3 (17.6) 69.8 (17.7) 84.3 (7.5)  
Seizure type  N = 126 N = 122 N = 4 <0.03 
     Absence, (%) 2 (1.6) 2 (1.6) 0 (0.0)  
     Tonic-Clonic, (%) 67 (53.2) 66 (54.1) 1 (25.0)  
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     Focal with impaired 
     awareness, (%) 
21 (16.7) 20 (16.4) 1 (25.0)  
     Focal aware, (%) 27 (21.4) 27 (22.1) 0 (0.0)  
     Myoclonic, (%) 5 (4.0) 4 (3.3) 1 (25.0)  
     Other, (%) 4 (3.2) 3 (2.5) 1 (25.0)  
Seizure frequency N = 128 N = 124 N = 4 0.64 
     0, (%) 49 (38.3) 46 (37.1) 3 (75.0)  
     1, (%) 55 (43.0) 54 (43.6) 1 (25.0)  
     2, (%) 9 (7.0) 9 (7.3) 0 (0.0)  
     3-20+, (%) 12 (9.4) 12 (9.7)  0 (0.0)  
     100+, (%) 3 (2.3) 3 (2.4) 0 (0.0)  
Epilepsy “yes” reason N = 388 N = 177 N = 211 <0.0001 
     2 unprovoked seizures, (%) 43 (11.1) 43 (24.3) 0 (0.0)  
     1 seizure + 60% probability, (%) 95 (24.5) 95 (53.7) 0 (0.0)  
     1 seizure + syndrome, (%) 3 (0.77) 3 (1.7) 0 (0.0)  
     Single seizure, (%) 7 (1.8) 9 (4.0) 0 (0.0)  
     Prophylaxis, (%) 29 (7.5) 29 (16.4) 0 (0.0)  
     Non-epileptic, (%) 201 (51.8) 0 (0.0) 201 (95.3)  
     Unknown, (%) 10 (2.6) 0 (0.0) 10 (4.7)  
Epilepsy syndrome  N = 119 N = 118 N = 1 0.34 
     Focal, (%)  56 (47.1) 56 (47.5) 0 (0.0)  
     Generalized, (%) 63 (52.9) 62 (52.5) 1 (100)  
Epilepsy etiology N = 117 N = 115 N = 2 0.64 
     Cryptogenic, (%) 32 (27.4) 31 (27.0) 1 (50.0)  
     Idiopathic, (%) 29 (24.8) 29 (25.2) 0 (0.0)  
     Symptomatic, (%) 56 (47.9) 55 (47.8) 1 (50.0)  
MRI Abnormal  N = 283 N = 118 N = 165 0.89 
     Normal MRI, (%) 42 (14.8) 17 (14.4) 25 (15.2)  
     Abnormal MRI, (%) 130 (45.9) 52 (44.1) 78 (47.3)  
     Normal CT, (%) 20 (7.1) 8 (6.8) 12 (7.3)  
     Abnormal CT, (%) 91 (32.2) 41 (34.8) 50 (30.3)  
EEG Abnormal N = 193 N = 126 N = 67 0.0019 
     Normal EEG, (%) 83 (43.0) 44 (34.9) 39 (58.2)  
     Abnormal EEG, (%) 110 (57.0) 82 (65.1) 28 (41.8)  
Veteran Status N = 367 N = 165 N = 202 0.21 
     Veteran, (%) 79 (20.4) 30 (17.0) 49 (23.2)  
     Not a Veteran, (%) 288 (74.2) 135 (76.3) 153 (72.5)  
     
*We confirmed demographic data, including vital status, gender, primary language, race, 
and the level of care received within the time frame (i.e. sub-divisions within the 
neurology department). When applicable and available, we abstracted number and type of 
medications, For patients with history of seizures, we gathered age at first seizure, seizure 
type, epilepsy syndrome, seizure frequency epilepsy syndrome and etiology, results of 
brain imaging (brain MRI or head CT), and results of EEG.  
The total N varies in each variable due to missing/insufficient data in charts. 
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 The comparison of cohorts with and without an epilepsy diagnoses shows 
statistically significant differences in ages in 2006, AEDs taken, number of medications 
taken and EEG results. According to the results, those with confirmed epilepsy had a 
mean age in 2006 younger than those without epilepsy (71.7 vs. 75.4; p<0.0001) (Figure 
6). The data demonstrates that individuals with epilepsy had more abnormal EEGs than 
those without epilepsy and on average take more medications. In addition, the percentage 
of the population of white subjects with epilepsy is lower than those of in the no epilepsy 
group (88.3 vs 95.6; p=0.015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Distribution of Age of Cohort in 2006. 
The age in 2006 were compared in the groups with and without epilepsy. The average age 
in 2006 of subjects with epilepsy was 71.7 (SD = 8.4), while those without epilepsy had 
an average age of 75.4 (SD = 8.4). 
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Greater Risk of Mortality in Comorbid Patients 
Of the 8275 eligible patient information gathered during the screening study time 
period (2006-2013), a total 250 (3%) patients were determined to have high possibility of 
having seizures associated with a diagnosis of Alzheimer’s disease or related dementias 
and 8025 (97%) with low possibility (Figure 7) based of associated ICD-9 codes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Sample Query. 
A. Query of Medicare Beneficiaries seen in MGH Neurology outpatient clinics between 
2006-2013 at least once, and who were older than 62 by 2013 
B1. Received at least one ICD-9 outpatient code suggestive of ADRD and one code 
suggestive of Epilepsy diagnosis  
B2. Did not receive any ICD-9 outpatient code suggestive of ADRD or Epilepsy   
C1. Selected all of the sample B1 for chart abstraction 
C2. Randomly selected 144 charts from B2 for chart abstraction 
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Among the eligible patients, the estimated cumulative risks for death within a 5 
years follow-up period were 36%. The mortality risk was greater among those individuals 
who had a possible history of seizures and dementia. These patients had a mortality rate 
of 56% (n=140) compared to those who did not (mortality risk ratio= 35%, n=2831, 
p<0.01) (Figure 8). Compared with the low risk group, history of seizures and dementia 
was associated with a 2.3-fold increase in risk for death within 5 years (OR: 2.3 [1.8-3.0], 
p<0.01).  
Multivariable logistic regression showed that having co-morbid seizures and 
dementia is associated with a greater mortality risk (Adjusted OR: 2.4 [1.6-3.1]), even 
after adjusting for age, gender, race, marital status, religion, and veteran status. In the 
sample selected for further validation (n=394), 197 (50%) died before 2016. The 
mortality rate was still greater among those who had possible history of seizures and 
dementia (rate = 56%, n=140) compared to those who did not (rate= 39.6%, n=57, 
p<0.01), as shown in Figure 9. 
After categorization using medical records as the gold standard (n=392), 83 (21%) 
patients had a confirmed history of epilepsy associated with a diagnosis of Alzheimer’s 
disease or related dementias and 309 (79%) did not. Two medical records did not have 
enough information and were excluded from this categorization. Among those 392 
patients with validated records, 195 (49.7%) died before 2016. The mortality rate 
remained greater among those who had confirmed history of seizures and dementia (rate 
= 59%, n=49) compared to those who did not (rate= 47%, n=146, p=0.05). The algorithm 
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for screening of patients with high possibility of history of seizures and dementia showed 
high sensitivity (76/83, 92%) and low specificity (137/309, 44%).   
 
Figure 8. Mortality Rates By Group. 
A.  Query of Medicare Beneficiaries seen in MGH Neurology outpatient clinics between 
2006-2013 at least once, and who were older than 62 by 2013 
B1. Received at least one ICD-9 outpatient code suggestive of ADRD and one code 
suggestive of Epilepsy diagnosis  
B2. Did not receive any ICD-9 outpatient code suggestive of ADRD or Epilepsy   
C1. Selected all of the sample B1 for chart abstraction 
C2. Randomly selected 144 charts from B2 for chart abstraction 
The number of deaths prior to 2006 and the percentage of sample is provided. 
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Figure 9. The Mortality Rate of Validated Sample. 
1. Total number of deaths in entire sample (197), 50% of entire sample 
2. Rates and Deaths of those with possible history of seizures and dementias. 
3. Rates and Deaths of those without history of seizures and dementias. 
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DISCUSSION 
 
 The present study provides insight into a serious public health issue of elderly 
mortality rates that has been seldom researched in the past. By utilizing a validation 
strategy with high sensitivity, patients could be identified with having been diagnosed 
with ADRD, ADRD and epilepsy, epilepsy or none at all. Results showed that mortality 
in elderly patients is extremely high and higher among patients with a history of seizures 
and dementia compared to other patients seen in the neurology clinic. By presenting 
mortality rates in a large sample over an extended period of time, a more accurate way to 
look at mortality in elderly was provided. The accuracy of the study was also increased 
by using mortality rate based on social security number (SSN) instead of relying on 
hospital discharge database. Even though the study provides a clear indication of the 
increased risk of death in comorbid patients, more research needs to be conducted in 
order to discover the probability of developing seizures post-ADRD diagnosis, treatment 
possibilities and comparisons of incident rates with other diagnoses. 
 
Seizures and ADRD 
 Seizures are more common in elderly patients (Faught et al., 2012). Determining 
how much cognitive impairment and at what stage of cognitive impairment increases the 
risk of developing epilepsy and seizures is a critical in discovering prophylactic 
measures. Even patients with mild cognitive impairment (MCI) and seizures or 
epileptiform activity have been shown to accelerate cognitive decline compared to those 
with just MCI. One study shows that those with MCI and epilepsy presented cognitive 
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decline 6.8 years earlier than those without seizure and those with AD and epilepsy 5.5 
years sooner than those without (64.3 vs 71.1 years; P= 0.2 and 64.8 vs 70.3 years; 
P=0.02 respectfully) (Vossel et al., 2013). This information indicates the importance of 
screening for seizures once an individual is identified for being at risk of cognitive 
decline. 
 Traditionally, epilepsy has been indicative of AD severity and disease 
progression, however, epilepsy can occur before the onset of cognitive symptoms in late-
onset AD by a few years (Agnese et al., 2011). In a study performed at MGH, seizures 
have been shown to precede or follow cognitive deterioration, ranging from 4.3 years 
before and 18.7 years after (Sarkis et al., 2016). As a result, the onset of a 
neurodegenerative condition should be examined while performing a differential 
diagnosis of patients with new-onset unprovoked seizures and cognitive impairments.  
 Nonetheless, the increased risk of seizures in those with ADRD has shown to be 
widely accepted due to the abundance of literature on the subject (Bernardi et al., 2010; 
Faught et al., 2012; Imfeld et al., 2013; Pugh et al., 2007; Ruggles et al., 2002; Vossel et 
al., 2013). Although our results did not show certain demographics that increase risk of 
developing seizures in ADRD, the study of Bernardi et al., showed that seizure frequency 
was 3x higher in men than in women and of the total patients with AD, 71.4% of those 
with seizure activity reported 2 or more attacks. Another study determines that younger 
AD patients have a higher probability of having seizures (Sherzai, et al.,  2014). This 
information can be critical in finding a link between early onset AD and the development 
of seizures that have not previously been identified. 
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The Evaluation Challenge 
 It has become increasingly clear that there is in fact an increased risk of death in 
elderly patients with AD and epilepsy. What is less clear is why this occurs. Much of this 
can be attributed to under-diagnosing the severity of cognitive impairment. Elderly 
patients need not be diagnosed with ADRD or epilepsy in order to be screened for 
cognitive decline. Currently, our healthcare system doesn’t perform neurological exams 
and imaging unless symptoms arise but this late identification can contribute to the 
increased mortality. Acute confusional state (ASC) is a common occurrence in elderly 
patients and has been related to seizure activity. The study by Naeije et al., studied the 
phenomenon of ACS as a result of both non-convulsive seizures and status epilepticus. 
They performed continuous EEGs on elderly patients with ACS and discovered that 53% 
of patients revealed epileptic anomalies that were not previously detected.  
On a molecular level, there is a dearth of information regarding the presence of 
any genetic relationship between seizures and ADRD. It is extremely unclear whether we 
can trace certain genes that not only increase the risk of developing ADRD but both 
seizures and ADRD. Although limited, research has begun looking into this and making 
progress. We are well aware of several gene mutations that cause AD, including APP, 
PSEN1 and PSEN2 (Tanzi & Bertram, 2005), but a recent study has shown that PSEN1 
may also lead to the seizure activity in AD patients. With approximately 180 known 
mutations on chromosome 14 of PSEN1, it is the most common cause of autosomal 
dominant AD (Larner, 2011). The results of Larner’s study revealed that 20% of recorded 
PSEN1 mutations have been found to be associated with epileptic seizures. What is 
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interesting is that this frequency may be understated due to non-recognition as 
epileptogenic in nature but classified as a symptom of the dementing disorder such as 
delirium or confusion. It is unbeknownst what specific mutations can lead to AD-related 
seizures but this discovery can lead to further research in genetics to discover other 
genetic mutations that increase the risk of developing seizures in patients with AD as well 
as those with other dementias.  
 
The Therapeutic Challenge 
With an estimated 20% of patients attending specialty epilepsy clinics who do not 
actually have epilepsy (Scheepers et al., 1998), patients given AED treatment are at a 
higher risk of cognitive decline and possible dementias. If AEDs can cause cognitive 
decline it is troubling to think about the detrimental cognitive and neurological affects of 
prescribing AEDs to patients with ADRD. In a study performed by Carter et al., they 
wanted to determine if utilizing AEDs was a risk factor for developing ADRD. Patients 
determined not to have cognitive impairment based on the Modified Mini-Mental (3MS) 
exam (score ≥ 78) at baseline and the results at 5-year follow-ups were compared to a 
control who did not have cognitive impairment and were not on AEDs (Carter et al., 
2007). The results showed that patients who used AEDs at baseline had a 3MS odds ratio 
of 2.11 for developing dementias, compared to those not taking them, thus indicative of 
the cognitive impact AEDs can have on patients. 
As we age, we become are more prone to other conditions and this general decline 
in health makes pharmacological treatment challenging. Elderly patients are likely to be 
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taking several medications for other medical issues and several of the first generation 
AEDs interact with several commonly used medications in the elderly (Jenssen & Schere, 
2010). For example, enzyme cytochrome P-450-inducing AEDs, including phenytoin, 
carbamazepine, and others have shown to be associated with osteoporosis, likely due to 
the increased metabolism of vitamin D (Pack & Morrell, 2004). Even though we have so 
many types of AEDs on the market for treatment of different types of epilepsy, all of 
them have side effects [Table 7] (Jenssen & Schere, 2010) and as a result, compliance is 
difficult with studies showing up to 41% of subjects non-adherent to AED treatment 
(Ettinger et al.,  2009). 
Table 7. Systematic Comparison of Antiepileptic Drugs. (Table amended from Jenssen 
& Schere, 2010). 
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Conclusion 
 The present study was successfully able to reveal the increased mortality in 
elderly Medicare patients with seizures and ADRD. Although this information is 
significant in acknowledging the critical need of improving differential diagnoses and 
evaluations, we did not find a way to systematically capture the reason of death for all 
patients of our validation sample. Our medical records review in review of death causes 
was incomplete due to missing data, patient death before follow-up, transfer of care, etc. 
We did not isolate groups with only seizures and only dementias for comparison but 
previous studies have reviewed these mortality rates. Another limitation to this study was 
the low specificity of the validation work. The abstraction work was limited to notes and 
images provided in the EHR, thus it was difficult to determine those with or without the 
disorders with relevant data was missing. In conclusion, much more research needs to be 
conducted to improve the quality of life and treatment options for patients suffering from 
seizures and ADRD with the goal of decreasing the mortality of these patients and 
reducing the public health concern. 
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